^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRAF V600

    i
    Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
    Entrez ID:
    673
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    1d
    LUNG-MAP Sub-Study: Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) (clinicaltrials.gov)
    P2, N=124, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive
    |
    FoundationOne® CDx
    |
    Retevmo (selpercatinib)
    1d
    MERAIODE: Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (clinicaltrials.gov)
    P2, N=40, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Jan 2026
    Trial completion • Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    BRAF V600E • BRAF V600 • HRAS mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    3d
    KiTZ-EPILOGUE-2024: Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) (2024-516896-34-00)
    P1/2, N=31, Not yet recruiting, Universitaetsklinikum Heidelberg AR
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF V600E • BRAF V600 • BRAF fusion
    |
    Ojemda (tovorafenib)
    5d
    Therapeutically Targetable Mutational Landscape of Anaplastic Thyroid Cancer. (PubMed, JCO Precis Oncol)
    Somatic PGVs in potentially targetable pathways were found in 72% of ATC tumors. Given the aggressiveness of ATC and the limited efficacy of current treatments, these findings support the rationale for biomarker-driven basket trials investigating the efficacy of targeted therapies in this population.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • NTRK (Neurotrophic receptor tyrosine kinase) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
    |
    BRAF V600E • BRAF V600 • HRD • NTRK fusion
    6d
    Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Rapa Therapeutics LLC | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    carboplatin • paclitaxel • temsirolimus • sirolimus • RAPA-201
    6d
    aCCeleR8-001: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=282, Recruiting, Shionogi | Trial completion date: Apr 2027 --> May 2028 | Trial primary completion date: Apr 2027 --> May 2028
    Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • S-531011
    7d
    HFB-200301-01: A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=72, Completed, HiFiBiO Therapeutics | Suspended --> Completed
    Trial completion • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    Tevimbra (tislelizumab-jsgr) • emunkitug (HFB200301)
    7d
    KiTZ-EPILOGUE-2024: Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) (2024-516896-34-00)
    P1/2, N=28, Not yet recruiting, Universitaetsklinikum Heidelberg AR
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene) • KIAA1549
    |
    BRAF V600E • BRAF V600 • BRAF fusion
    |
    Ojemda (tovorafenib)
    7d
    Identification of BRAF V600E Mutation in Cerebrospinal Fluid Aids in Diagnosing Leptomeningeal Carcinomatosis Arising From Pleomorphic Xanthoastrocytoma: A Case Report. (PubMed, Cancer Rep (Hoboken))
    This case highlights the utility of next-generation sequencing as a means of non-invasively diagnosing leptomeningeal disease in recurrent PXA and potentially in other cancer types as well.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    7d
    TERT promoter variants in risk stratification of Polish patients with papillary thyroid carcinoma. (PubMed, Pol Arch Intern Med)
    Detection of TERTp variants should be considered in routine diagnostic procedures, as this would significantly improve the ability to classify patients into risk groups.
    Journal
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    8d
    Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance (clinicaltrials.gov)
    P=N/A, N=40, Enrolling by invitation, Chang Gung Memorial Hospital | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • BRAF V600 • HER-2 mutation • RET fusion • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • MET mutation • KRAS G12
    8d
    Androgen receptor-dependent DRAM1 activation drives autophagic resistance to BRAF inhibitors in BRAFV600-mutant melanoma. (PubMed, Cell Death Dis)
    Functional studies reveal that AR-driven autophagy confers resistance to BRAFi by enhancing cellular survival under therapeutic stress. Our findings establish AR-regulated autophagy as a critical resistance mechanism and provide preclinical evidence for combining AR-targeting PROTAC degrader ARV110 with autophagy inhibitors to overcome BRAFi resistance.
    Journal
    |
    AR (Androgen receptor)
    |
    BRAF mutation • BRAF V600
    |
    bavdegalutamide (ARV-110)